Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025GlobeNewsWire • 09/03/25
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 CongressGlobeNewsWire • 09/02/25
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top EstimatesZacks Investment Research • 08/06/25
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/06/25
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 07/31/25
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025GlobeNewsWire • 07/23/25
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)GlobeNewsWire • 07/18/25
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)GlobeNewsWire • 06/23/25
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)GlobeNewsWire • 06/18/25
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/29/25
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of CardiologyGlobeNewsWire • 05/19/25
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/13/25
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/13/25
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 05/06/25
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025GlobeNewsWire • 05/06/25
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/25
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo NordiskBenzinga • 03/28/25